Review

ubc9 (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc ubc9

a Immunofluorescence images and quantification (n = 20) of SUMO1 (green) and SUMO2/3 (red) conjugation in RAW264.7 cells with or without STM 14028S infection (4 hpi). Scale bar, 10 µm. b Core SUMO cycle enzymes and their corresponding primary genes (blue). c, d Transcriptomic and proteomic analyses of SUMO cycle enzyme expression in RAW264.7 cells infected with STM 14028S vs uninfected controls (4 hpi; n = 3). e <t>UBC9</t> mRNA expression in RAW264.7 cells during STM 14028S infection (0-6 hpi; n = 3). f Immunoblot analysis and quantification of UBC9 protein levels in STM 14028S-infected RAW264.7 cells (0-6 hpi; n = 3). *P < 0.05; ***P < 0.001; ns, not significant.

Ubc9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ubc9/Ubc9+XP+Rabbit+mAb/bio_rxiv__64898__2026__03__06__710069-241-8-9
Average 93 stars, based on 47 article reviews

ubc9 - by Bioz Stars, 2026-10

93/100 stars

Images

1) Product Images from "A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation"

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

Journal: bioRxiv

doi: 10.64898/2026.03.06.710069

Figure Legend Snippet: a Immunofluorescence images and quantification (n = 20) of SUMO1 (green) and SUMO2/3 (red) conjugation in RAW264.7 cells with or without STM 14028S infection (4 hpi). Scale bar, 10 µm. b Core SUMO cycle enzymes and their corresponding primary genes (blue). c, d Transcriptomic and proteomic analyses of SUMO cycle enzyme expression in RAW264.7 cells infected with STM 14028S vs uninfected controls (4 hpi; n = 3). e UBC9 mRNA expression in RAW264.7 cells during STM 14028S infection (0-6 hpi; n = 3). f Immunoblot analysis and quantification of UBC9 protein levels in STM 14028S-infected RAW264.7 cells (0-6 hpi; n = 3). *P < 0.05; ***P < 0.001; ns, not significant.

Techniques Used: Immunofluorescence, Conjugation Assay, Infection, Expressing, Western Blot

a Schematic of the Y2H screening workflow and pairwise interaction validation strategy. b Representative positive colonies on selective plates; four colonies (blue arrows) correspond to Ube2i (encoding UBC9). c Sequencing analysis of positive clones showing that four independent clones encode Ube2i (orange). d Pairwise interaction assay validating the interaction between SseK1 and UBC9. e Co-IP in HEK293T cells confirming the interaction between SseK1 and UBC9. f In vitro pull-down assay demonstrating direct binding between purified SseK1 and UBC9. g BLI analysis showing the binding kinetics between SseK1 and UBC9 in vitro .

Figure Legend Snippet: a Schematic of the Y2H screening workflow and pairwise interaction validation strategy. b Representative positive colonies on selective plates; four colonies (blue arrows) correspond to Ube2i (encoding UBC9). c Sequencing analysis of positive clones showing that four independent clones encode Ube2i (orange). d Pairwise interaction assay validating the interaction between SseK1 and UBC9. e Co-IP in HEK293T cells confirming the interaction between SseK1 and UBC9. f In vitro pull-down assay demonstrating direct binding between purified SseK1 and UBC9. g BLI analysis showing the binding kinetics between SseK1 and UBC9 in vitro .

Techniques Used: Biomarker Discovery, Sequencing, Clone Assay, Co-Immunoprecipitation Assay, In Vitro, Pull Down Assay, Binding Assay, Purification

a HEK293T cells expressing Flag-UBC9 were infected with STM WT or Δ sseK1 , followed by immunoprecipitation and immunoblot analysis of UBC9 Arg-GlcNAcylation. b In vitro enzymatic assays showing Arg-GlcNAcylation of bacterially expressed 6×His-UBC9, detected by immunoblotting. c MS/MS spectrum of Arg-GlcNAcylated Flag-UBC9 peptides. Corresponding b and y ions are indicated along the peptide sequence above the spectrum. d Immunoblot analysis and quantification (normalized to Coomassie-stained protein, n = 3) of Arg-GlcNAcylation of UBC9 and UBC9 R17A. **P < 0.01.

Figure Legend Snippet: a HEK293T cells expressing Flag-UBC9 were infected with STM WT or Δ sseK1 , followed by immunoprecipitation and immunoblot analysis of UBC9 Arg-GlcNAcylation. b In vitro enzymatic assays showing Arg-GlcNAcylation of bacterially expressed 6×His-UBC9, detected by immunoblotting. c MS/MS spectrum of Arg-GlcNAcylated Flag-UBC9 peptides. Corresponding b and y ions are indicated along the peptide sequence above the spectrum. d Immunoblot analysis and quantification (normalized to Coomassie-stained protein, n = 3) of Arg-GlcNAcylation of UBC9 and UBC9 R17A. **P < 0.01.

Techniques Used: Expressing, Infection, Immunoprecipitation, Western Blot, In Vitro, Tandem Mass Spectroscopy, Sequencing, Staining

a Crystal structure of the UBC9-SUMO1 complex (PDB: 2UYZ). b Predicted structure of the UBC9-SUMO2 complex generated using AlphaFold3. Enlarged views of the UBC9-SUMO1 and UBC9-SUMO2 interfaces are highlighted in black boxes. Residues forming hydrogen bonds with UBC9 R17 are shown in stick representation. c Purification of 6×His-UBC9 from E. coli BL21(DE3) co-expressing pSseK1 and pUBC9, followed by immunoblot analysis of UBC9 Arg-GlcNAcylation. d Purification of SUMO1 and SUMO2 proteins from E. coli BL21(DE3) harboring pSUMO1 or pSUMO2, respectively. M, molecular weight marker. e, f MST analysis of the binding affinities between SUMO1 or SUMO2 and unmodified UBC9 or Arg-GlcNAcylated UBC9.

Figure Legend Snippet: a Crystal structure of the UBC9-SUMO1 complex (PDB: 2UYZ). b Predicted structure of the UBC9-SUMO2 complex generated using AlphaFold3. Enlarged views of the UBC9-SUMO1 and UBC9-SUMO2 interfaces are highlighted in black boxes. Residues forming hydrogen bonds with UBC9 R17 are shown in stick representation. c Purification of 6×His-UBC9 from E. coli BL21(DE3) co-expressing pSseK1 and pUBC9, followed by immunoblot analysis of UBC9 Arg-GlcNAcylation. d Purification of SUMO1 and SUMO2 proteins from E. coli BL21(DE3) harboring pSUMO1 or pSUMO2, respectively. M, molecular weight marker. e, f MST analysis of the binding affinities between SUMO1 or SUMO2 and unmodified UBC9 or Arg-GlcNAcylated UBC9.

Techniques Used: Generated, Purification, Expressing, Western Blot, Molecular Weight, Marker, Binding Assay

a Immunoblot analysis of UBC9 Arg-GlcNAcylation mediated by SseK1, SseK2, or SseK3. b AlphaFold-predicted structures of SseK1 (aa 29-336, red), SseK2 (aa 29-348, yellow), and SseK3 (aa 29-335, green), shown with structural alignment using PyMOL. c AlphaFold-modeled structure of the SseK1-UBC9 complex. The enlarged view of the lid-domain region is boxed in black. Residues in the SseK1 lid domain forming hydrogen bonds with UBC9 are shown in stick representation. d Sequence alignment of SseK1, SseK2, and SseK3 generated using ESPript 3.0. e Immunoblot analysis of UBC9 Arg-GlcNAcylation mediated by SseK1, SseK1 A332_Q336del, SseK3, and SseK3 R332delinsARHVQ. f Immunoblot analysis of SUMO2/3 conjugation in RAW264.7 cells infected with STM Δ sseK1 , STM Δ sseK1 complemented with SseK1, or STM Δ sseK1 complemented with either SseK1 D223_D225delinsAAA or SseK1 A332_Q336del (4 hpi). g Phylogenetic analysis of Salmonella Typhimurium SseK1 homologs. Protein sequences homologous to SseK1 (UniProt accession: A0A0H3NK84) were identified using BLASTP analysis against the UniProtKB reference proteomes and Swiss-Prot databases. Sequences with an E-value < 0.05 were selected for phylogenetic analysis. The phylogenetic tree was constructed and visualized using the Interactive Tree of Life (iTOL) online tool.

Figure Legend Snippet: a Immunoblot analysis of UBC9 Arg-GlcNAcylation mediated by SseK1, SseK2, or SseK3. b AlphaFold-predicted structures of SseK1 (aa 29-336, red), SseK2 (aa 29-348, yellow), and SseK3 (aa 29-335, green), shown with structural alignment using PyMOL. c AlphaFold-modeled structure of the SseK1-UBC9 complex. The enlarged view of the lid-domain region is boxed in black. Residues in the SseK1 lid domain forming hydrogen bonds with UBC9 are shown in stick representation. d Sequence alignment of SseK1, SseK2, and SseK3 generated using ESPript 3.0. e Immunoblot analysis of UBC9 Arg-GlcNAcylation mediated by SseK1, SseK1 A332_Q336del, SseK3, and SseK3 R332delinsARHVQ. f Immunoblot analysis of SUMO2/3 conjugation in RAW264.7 cells infected with STM Δ sseK1 , STM Δ sseK1 complemented with SseK1, or STM Δ sseK1 complemented with either SseK1 D223_D225delinsAAA or SseK1 A332_Q336del (4 hpi). g Phylogenetic analysis of Salmonella Typhimurium SseK1 homologs. Protein sequences homologous to SseK1 (UniProt accession: A0A0H3NK84) were identified using BLASTP analysis against the UniProtKB reference proteomes and Swiss-Prot databases. Sequences with an E-value < 0.05 were selected for phylogenetic analysis. The phylogenetic tree was constructed and visualized using the Interactive Tree of Life (iTOL) online tool.

Techniques Used: Western Blot, Sequencing, Generated, Conjugation Assay, Infection, Construct

Approximately two hours after entering macrophages, Salmonella activates its T3SS-2 to deliver effector proteins, including SseK1, SseK2 and SseK3, into the cytoplasm. Among these effectors, SseK1 uniquely engages UBC9 through its unique lid domain and catalyzes arginine-GlcNAcylation of UBC9 at residue R17. This modification prevents UBC9 from forming the UBC9-SUMO thioester intermediate, thereby blocking SUMO conjugation onto a broad set of antimicrobial substrates and impairing their activity, stability or localization. By blocking this SUMO-dependent arm of the host immune response, Salmonella evades host antimicrobial defenses, thereby promoting its survival and enhancing virulence.

Figure Legend Snippet: Approximately two hours after entering macrophages, Salmonella activates its T3SS-2 to deliver effector proteins, including SseK1, SseK2 and SseK3, into the cytoplasm. Among these effectors, SseK1 uniquely engages UBC9 through its unique lid domain and catalyzes arginine-GlcNAcylation of UBC9 at residue R17. This modification prevents UBC9 from forming the UBC9-SUMO thioester intermediate, thereby blocking SUMO conjugation onto a broad set of antimicrobial substrates and impairing their activity, stability or localization. By blocking this SUMO-dependent arm of the host immune response, Salmonella evades host antimicrobial defenses, thereby promoting its survival and enhancing virulence.

Techniques Used: Residue, Modification, Blocking Assay, Conjugation Assay, Activity Assay

Immunohistochemistry:

Article Title: The Role of SUMO1 Modification of SOX9 in Cartilage Development Stimulated by Zinc Ions in Mice.
Article Snippet: We stained the deparaffinized sections with HE (Solarbio G1120) or Safranin O (Solarbio G1371) and examined them under a microscope (Olympus cellSens Entry 1.16, Olympus Corporation, Japan) after air-drying and mounting with neutral gum. .. For IHC, we blocked endogenous peroxidase activity, performed antigen retrieval, and incubated the sections with goat serum before adding primary antibodies (anti-SUMO1 (Abcam ab32058), anti-SUMO2/3 (Abcam ab81371), anti-UBC9 (CST #4918)) and secondary antibodies sequentially. ..

Activity Assay:

Incubation:

Article Title: The Role of SUMO1 Modification of SOX9 in Cartilage Development Stimulated by Zinc Ions in Mice.
Article Snippet: .. We incubated the membranes with primary antibodies (antiSUMO1 (Abcam ab32058), anti-SUMO2/3 (Abcam ab81371), anti-UBC9 (CST #4918), antiSOX9 (Abcam ab185230) anti-MMP13 (Abcam ab219620), anti-Collagen II (Abcam ab307674), anti-RUNX2 (Abcam ab236639), anti-aggrecan (Abcam ab3778)), and secondary antibodies (goat anti-mouse IgG-HRP (Abcam ab6789) or goat anti-rabbit IgG-HRP (Abcam ab6721)) sequentially before developing and exposing them. ..

Western Blot:

Article Title: IRX3 controls a SUMOylation-dependent differentiation switch in adipocyte precursor cells.
Article Snippet: .. The following primary antibodies were used for WB: antiSUMO2/3 (ab3742, Abcam), anti-SUMO1 (ab32058, Abcam), anti-AM (AB_2793779, Active Motif), anti-ACTB (ab6276, Abcam), anti-GAPDH (MAB374, Millipore), anti-VINCULIN (ab18058, Abcam), (anti-SENP1 (ab236094, Abcam), anti-SENP5 (19529-1-AP, Proteintech), anti-UBA2 (8688S, Cell signaling), anti-UBC9 (4786S, Cell Signaling) and anti-SAE1 (ab185949, Abcam). ..

Article Title: IRX3 controls a SUMOylation-dependent differentiation switch in adipocyte precursor cells
Article Snippet: .. The following primary antibodies were used for WB: anti-SUMO2/3 (ab3742, Abcam), anti-SUMO1 (ab32058, Abcam), anti-AM (AB_2793779, Active Motif), anti-ACTB (ab6276, Abcam), anti-GAPDH (MAB374, Millipore), anti-VINCULIN (ab18058, Abcam), (anti-SENP1 (ab236094, Abcam), anti-SENP5 (19529-1-AP, Proteintech), anti-UBA2 (8688S, Cell signaling), anti-UBC9 (4786S, Cell Signaling) and anti-SAE1 (ab185949, Abcam). ..

Image Search Results

Journal: bioRxiv

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

doi: 10.64898/2026.03.06.710069

Figure Lengend Snippet: a Immunofluorescence images and quantification (n = 20) of SUMO1 (green) and SUMO2/3 (red) conjugation in RAW264.7 cells with or without STM 14028S infection (4 hpi). Scale bar, 10 µm. b Core SUMO cycle enzymes and their corresponding primary genes (blue). c, d Transcriptomic and proteomic analyses of SUMO cycle enzyme expression in RAW264.7 cells infected with STM 14028S vs uninfected controls (4 hpi; n = 3). e UBC9 mRNA expression in RAW264.7 cells during STM 14028S infection (0-6 hpi; n = 3). f Immunoblot analysis and quantification of UBC9 protein levels in STM 14028S-infected RAW264.7 cells (0-6 hpi; n = 3). *P < 0.05; ***P < 0.001; ns, not significant.

Article Snippet: Unique primary antibodies used in this study included UBC9 (CST, #4786), SUMO1 (Proteintech, 67557-1-lg), SUMO2/3 (Proteintech, 67154-1-lg), arginine-GlcNAcylation antibody (Abcam, EPR18251), Myd88 (Proteintech, 67969-1-lg), HSPA8 (Proteintech, 10654-1-AP), PDCD4 (Proteintech, 84162-3-RR).

Techniques: Immunofluorescence, Conjugation Assay, Infection, Expressing, Western Blot

Journal: bioRxiv

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

doi: 10.64898/2026.03.06.710069

Figure Lengend Snippet: a Schematic of the Y2H screening workflow and pairwise interaction validation strategy. b Representative positive colonies on selective plates; four colonies (blue arrows) correspond to Ube2i (encoding UBC9). c Sequencing analysis of positive clones showing that four independent clones encode Ube2i (orange). d Pairwise interaction assay validating the interaction between SseK1 and UBC9. e Co-IP in HEK293T cells confirming the interaction between SseK1 and UBC9. f In vitro pull-down assay demonstrating direct binding between purified SseK1 and UBC9. g BLI analysis showing the binding kinetics between SseK1 and UBC9 in vitro .

Techniques: Biomarker Discovery, Sequencing, Clone Assay, Co-Immunoprecipitation Assay, In Vitro, Pull Down Assay, Binding Assay, Purification

Journal: bioRxiv

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

doi: 10.64898/2026.03.06.710069

Figure Lengend Snippet: a HEK293T cells expressing Flag-UBC9 were infected with STM WT or Δ sseK1 , followed by immunoprecipitation and immunoblot analysis of UBC9 Arg-GlcNAcylation. b In vitro enzymatic assays showing Arg-GlcNAcylation of bacterially expressed 6×His-UBC9, detected by immunoblotting. c MS/MS spectrum of Arg-GlcNAcylated Flag-UBC9 peptides. Corresponding b and y ions are indicated along the peptide sequence above the spectrum. d Immunoblot analysis and quantification (normalized to Coomassie-stained protein, n = 3) of Arg-GlcNAcylation of UBC9 and UBC9 R17A. **P < 0.01.

Techniques: Expressing, Infection, Immunoprecipitation, Western Blot, In Vitro, Tandem Mass Spectroscopy, Sequencing, Staining

Journal: bioRxiv

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

doi: 10.64898/2026.03.06.710069

Figure Lengend Snippet: a Crystal structure of the UBC9-SUMO1 complex (PDB: 2UYZ). b Predicted structure of the UBC9-SUMO2 complex generated using AlphaFold3. Enlarged views of the UBC9-SUMO1 and UBC9-SUMO2 interfaces are highlighted in black boxes. Residues forming hydrogen bonds with UBC9 R17 are shown in stick representation. c Purification of 6×His-UBC9 from E. coli BL21(DE3) co-expressing pSseK1 and pUBC9, followed by immunoblot analysis of UBC9 Arg-GlcNAcylation. d Purification of SUMO1 and SUMO2 proteins from E. coli BL21(DE3) harboring pSUMO1 or pSUMO2, respectively. M, molecular weight marker. e, f MST analysis of the binding affinities between SUMO1 or SUMO2 and unmodified UBC9 or Arg-GlcNAcylated UBC9.

Techniques: Generated, Purification, Expressing, Western Blot, Molecular Weight, Marker, Binding Assay

Journal: bioRxiv

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

doi: 10.64898/2026.03.06.710069

Figure Lengend Snippet: a Immunoblot analysis of UBC9 Arg-GlcNAcylation mediated by SseK1, SseK2, or SseK3. b AlphaFold-predicted structures of SseK1 (aa 29-336, red), SseK2 (aa 29-348, yellow), and SseK3 (aa 29-335, green), shown with structural alignment using PyMOL. c AlphaFold-modeled structure of the SseK1-UBC9 complex. The enlarged view of the lid-domain region is boxed in black. Residues in the SseK1 lid domain forming hydrogen bonds with UBC9 are shown in stick representation. d Sequence alignment of SseK1, SseK2, and SseK3 generated using ESPript 3.0. e Immunoblot analysis of UBC9 Arg-GlcNAcylation mediated by SseK1, SseK1 A332_Q336del, SseK3, and SseK3 R332delinsARHVQ. f Immunoblot analysis of SUMO2/3 conjugation in RAW264.7 cells infected with STM Δ sseK1 , STM Δ sseK1 complemented with SseK1, or STM Δ sseK1 complemented with either SseK1 D223_D225delinsAAA or SseK1 A332_Q336del (4 hpi). g Phylogenetic analysis of Salmonella Typhimurium SseK1 homologs. Protein sequences homologous to SseK1 (UniProt accession: A0A0H3NK84) were identified using BLASTP analysis against the UniProtKB reference proteomes and Swiss-Prot databases. Sequences with an E-value < 0.05 were selected for phylogenetic analysis. The phylogenetic tree was constructed and visualized using the Interactive Tree of Life (iTOL) online tool.

Techniques: Western Blot, Sequencing, Generated, Conjugation Assay, Infection, Construct

Journal: bioRxiv

Article Title: A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation

doi: 10.64898/2026.03.06.710069

Figure Lengend Snippet: Approximately two hours after entering macrophages, Salmonella activates its T3SS-2 to deliver effector proteins, including SseK1, SseK2 and SseK3, into the cytoplasm. Among these effectors, SseK1 uniquely engages UBC9 through its unique lid domain and catalyzes arginine-GlcNAcylation of UBC9 at residue R17. This modification prevents UBC9 from forming the UBC9-SUMO thioester intermediate, thereby blocking SUMO conjugation onto a broad set of antimicrobial substrates and impairing their activity, stability or localization. By blocking this SUMO-dependent arm of the host immune response, Salmonella evades host antimicrobial defenses, thereby promoting its survival and enhancing virulence.

Techniques: Residue, Modification, Blocking Assay, Conjugation Assay, Activity Assay

FOXL2 SUMOylation intricately regulates increased expression in CAFs. ( A ) SUMOylation sites of FOXL2 was analyzed by SUMOplot™ analysis. Shown are the top 7 predicted lysine residues; ( B ) In vitro sumoylation assay was employed to confirm the predicted SUMOylation sites using HA-tagged wild-type (WT), or the K25R, K87R, K114R, K150R, and 4KR (where K25, K87, K114 and K150 were all mutated to R). Shown is a representative blot and densitometry analysis of SUMOylated-FOXL2/Total FOXL2; ( C ) The association between SUMOylation and FOXL2 stability was determined by western blotting in HEK-293T cells using α-HA. Cells were transfected with either HA-FOXL2-WT or HA-FOXL2-K25/87R (double mutant, 2KR). The membrane was stripped and re-probed with GAPDH to confirm equivalent loading. Shown is a representative blot and densitometry analysis of three technical replicates; ( D ) Cells were transfected with HA-FOXL2-WT or, HA-FOXL2-2KR ± His-SUMO1. CHX (100 µg/ml) was added to inhibit translation allowing tracking of FOXL2 stability in the presence and absence of His-SUMO1. Blots were probed with α-HA and re-probed with GAPDH to confirm equivalent loading. Shown is a representative blot and densitometry analysis of three technical replicates; ( E ) DMSO (control), MG132 (proteasome inhibitor) or chloroquine (lysosome inhibitor) were added into HEK-293T cells transfected with HA-FOXL2-WT or HA-FOXL2-2KR, before CHX (100 µg/ml) was added. Blots were probed with α-HA and re-probed with GAPDH to confirm equivalent loading. Shown is a representative blot; ( F ) IP assay was used to test the association between FOXL2 SUMOylation and ubiquitination. Lysates obtained from HEK-293T cells transfected with HA-FOXL2-WT or HA-FOXL2-2KR, along with FLAG-UBC9, were immunoprecipitated using α-HA antibody and then probed with α-FLAG antibody. Shown is a representative blot; *, *** P < 0.05, P < 0.001

Journal: BMC Cancer

Article Title: FOXL2 + cancer-associated fibroblasts enhances epithelial ovarian cancer development via TGFβ/Smad signaling

doi: 10.1186/s12885-025-15364-6

Figure Lengend Snippet: FOXL2 SUMOylation intricately regulates increased expression in CAFs. ( A ) SUMOylation sites of FOXL2 was analyzed by SUMOplot™ analysis. Shown are the top 7 predicted lysine residues; ( B ) In vitro sumoylation assay was employed to confirm the predicted SUMOylation sites using HA-tagged wild-type (WT), or the K25R, K87R, K114R, K150R, and 4KR (where K25, K87, K114 and K150 were all mutated to R). Shown is a representative blot and densitometry analysis of SUMOylated-FOXL2/Total FOXL2; ( C ) The association between SUMOylation and FOXL2 stability was determined by western blotting in HEK-293T cells using α-HA. Cells were transfected with either HA-FOXL2-WT or HA-FOXL2-K25/87R (double mutant, 2KR). The membrane was stripped and re-probed with GAPDH to confirm equivalent loading. Shown is a representative blot and densitometry analysis of three technical replicates; ( D ) Cells were transfected with HA-FOXL2-WT or, HA-FOXL2-2KR ± His-SUMO1. CHX (100 µg/ml) was added to inhibit translation allowing tracking of FOXL2 stability in the presence and absence of His-SUMO1. Blots were probed with α-HA and re-probed with GAPDH to confirm equivalent loading. Shown is a representative blot and densitometry analysis of three technical replicates; ( E ) DMSO (control), MG132 (proteasome inhibitor) or chloroquine (lysosome inhibitor) were added into HEK-293T cells transfected with HA-FOXL2-WT or HA-FOXL2-2KR, before CHX (100 µg/ml) was added. Blots were probed with α-HA and re-probed with GAPDH to confirm equivalent loading. Shown is a representative blot; ( F ) IP assay was used to test the association between FOXL2 SUMOylation and ubiquitination. Lysates obtained from HEK-293T cells transfected with HA-FOXL2-WT or HA-FOXL2-2KR, along with FLAG-UBC9, were immunoprecipitated using α-HA antibody and then probed with α-FLAG antibody. Shown is a representative blot; *, *** P < 0.05, P < 0.001

Article Snippet: The different primary antibodies used were α-SUMO1 (67559-1-Ig, 1:3000), α-UBC9 (10070-1-AP, 1:2000), α-Vimentin (10366-1-AP, 1:5000), α-N-cadherin (22018-1-AP, 1:5000), α-E-cadherin (20874-1-AP, 1:20000) (Proteintech, Wuhan, China); α-HA (A02041, 1:800), α-His (A02050, 1:800), α-Flag (A02010, 1:800) (Abbkine, Wuhan, China); α-FOXL2 (ab246511, 1:1000), α-Snail (ab216347, 1:1000) (Abcam, Cambridge, MA, USA); and, α-Smad2/3 (D7G7, 1:1000), α-p-Smad2 (Ser465/467)/Smad3 (Ser423/425) (D27F4, 1:1000) (CST, Boston, MA, USA).

Techniques: Expressing, In Vitro, Western Blot, Transfection, Mutagenesis, Membrane, Control, Ubiquitin Proteomics, Immunoprecipitation

FOXL2 SUMOylation requires SUMO1 and UBC9/UBE2I. ( A ) Putative interaction of FOXL2 with SUMO1, SUMO2, SUMO3, and SUMO4 was detected by String analysis ( https://cn.string-db.org/ ); ( B ) In vitro sumoylation assay was employed to confirm String analysis’s prediction of SUMO1, HEK-293T cells were transfected with HA-FOXL2-WT, FLAG-UBC9, and His-SUMO1-4. In vitro SUMOylation assay using Ni 2+ -NTA pull-down determined that FOXL2 was mainly modified by SUMO1. Shown is a representative blot; ( C ) In vitro sumoylation assay was employed to determine whether UBC9 is compulsorily required for FOXL2 SUMOylation. HEK-293T cells were transfected with HA-FOXL2-WT and His-SUMO1 ± FLAG-UBC9. In vitro SUMOylation using Ni 2+ -NTA pull-down assay determined that UBC9 is required for FOXL2 SUMOylation. Shown is a representative blot; ( D ) In vitro sumoylation assay was employed to determine whether UBC9 is compulsorily required for FOXL2 SUMOylation in CAFs. CAFs were transduced using either a non-targeting control shRNA or shRNA targeting UBC9 . Transduced cells were transfected with HA-FOXL2-WT and His-SUMO1. In vitro SUMOylation using Ni 2+ -NTA pull-down assay determined that UBC9 is required for FOXL2 SUMOylation. Shown is a representative blot

Journal: BMC Cancer

Article Title: FOXL2 + cancer-associated fibroblasts enhances epithelial ovarian cancer development via TGFβ/Smad signaling

doi: 10.1186/s12885-025-15364-6

Figure Lengend Snippet: FOXL2 SUMOylation requires SUMO1 and UBC9/UBE2I. ( A ) Putative interaction of FOXL2 with SUMO1, SUMO2, SUMO3, and SUMO4 was detected by String analysis ( https://cn.string-db.org/ ); ( B ) In vitro sumoylation assay was employed to confirm String analysis’s prediction of SUMO1, HEK-293T cells were transfected with HA-FOXL2-WT, FLAG-UBC9, and His-SUMO1-4. In vitro SUMOylation assay using Ni 2+ -NTA pull-down determined that FOXL2 was mainly modified by SUMO1. Shown is a representative blot; ( C ) In vitro sumoylation assay was employed to determine whether UBC9 is compulsorily required for FOXL2 SUMOylation. HEK-293T cells were transfected with HA-FOXL2-WT and His-SUMO1 ± FLAG-UBC9. In vitro SUMOylation using Ni 2+ -NTA pull-down assay determined that UBC9 is required for FOXL2 SUMOylation. Shown is a representative blot; ( D ) In vitro sumoylation assay was employed to determine whether UBC9 is compulsorily required for FOXL2 SUMOylation in CAFs. CAFs were transduced using either a non-targeting control shRNA or shRNA targeting UBC9 . Transduced cells were transfected with HA-FOXL2-WT and His-SUMO1. In vitro SUMOylation using Ni 2+ -NTA pull-down assay determined that UBC9 is required for FOXL2 SUMOylation. Shown is a representative blot

Techniques: In Vitro, Transfection, Modification, Pull Down Assay, Control, shRNA

Review

ubc9 (Cell Signaling Technology Inc)

Structured Review

Images

1) Product Images from "A bacterial effector blocks SUMOylation by steric occlusion of UBC9 via arginine-GlcNAcylation"

Related Articles

Immunohistochemistry:

Activity Assay:

Incubation:

Western Blot:

Similar Products

Image Search Results